Menu

Federal Ban Lifted on Studying Most Dangerous Pathogens

Only a few labs will earn funding for such “gain-of-function” research on SARS, MERS, and other deadly diseases.

Dec 20, 2017
Kerry Grens

WIKIMEDIA, THE US FOOD AND DRUG ADMINISTRATIONAs of Tuesday (December 19), the US government has ended its moratorium on funding “gain-of-function” research on deadly pathogens. These studies allow for the manipulation of potentially pandemic-causing viruses.

According to The Washington Post, National Institutes of Health Director Francis Collins told reporters that the government has developed a new, stringent policy outlining the justifications necessary for such risky investigations to receive money. “This kind of research can only be conducted in a very few places that have the highest level of containment,” Collins said.

The ban emerged in 2014 after a series of concerning events. In 2012, researchers had developed an influenza virus that ferrets could catch through the air. Then in 2014, biosafety mishaps shook up federal agencies—one involved staff being exposed to anthrax, another with forgotten vials of smallpox that were discovered in a storage facility.

The ban’s end “is very good news for laboratories interested in understanding the threat of natural pathogens to the human population,” James Paulson, a researcher at The Scripps Research Institute, tells NPR.

But the scientific community is not in complete agreement that gain-of-function studies are warranted. Marc Lipsitch, an epidemiologist at the Harvard T.H. Chan School of Public Health tells Nature that such studies “have done almost nothing to improve our preparedness for pandemics—yet they risked creating an accidental pandemic.” 

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Download this application note from ACEA Biosciences, Inc., to find out how to perform an immunophenotypic analysis of a human blood sample utilizing 13 fluorescent markers using a compact benchtop flow cytometer equipped with 3 lasers!